XML 56 R26.htm IDEA: XBRL DOCUMENT v3.20.4
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The Company conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and operating income. The accounting policies of the segments are substantially the same as those described in Note 2. Segment net sales and segment operating income are based on internally derived standard foreign exchange rates, which may differ from year to year, and do not include inter-segment profits. Because of the interdependence of the reportable segments,
the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include net interest expense, global marketing expenses, corporate research and development expenses, manufacturing variances, corporate headquarters costs, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, changes in the fair value of contingent consideration liabilities, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment operating income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment, and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Years Ended December 31,
 202020192018
Segment Net Sales   
United States$2,516.8 $2,532.7 $2,055.2 
Europe945.2 926.1 826.4 
Japan448.6 441.4 398.4 
Rest of World451.5 433.3 396.0 
Total segment net sales$4,362.1 $4,333.5 $3,676.0 
Segment Operating Income  
United States$1,727.3 $1,742.3 $1,368.1 
Europe479.3 472.0 394.8 
Japan286.4 272.3 237.0 
Rest of World150.1 127.9 115.6 
Total segment operating income$2,643.1 $2,614.5 $2,115.5 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated income before provision for income taxes ("pre-tax income") (in millions):
 Years Ended December 31,
 202020192018
Net Sales Reconciliation   
Segment net sales$4,362.1 $4,333.5 $3,676.0 
Foreign currency24.2 14.5 46.8 
Consolidated net sales$4,386.3 $4,348.0 $3,722.8 
Pre-tax Income Reconciliation  
Segment operating income$2,643.1 $2,614.5 $2,115.5 
Unallocated amounts:
Corporate items(1,358.0)(1,439.7)(1,058.1)
Special charges— (64.6)(116.2)
Intellectual property litigation expenses, net(405.4)(33.4)(214.0)
Change in fair value of contingent consideration liabilities, net(13.6)6.1 5.7 
Foreign currency31.5 63.9 15.3 
Consolidated operating income897.6 1,146.8 748.2 
Non-operating income19.1 19.7 13.2 
Consolidated pre-tax income$916.7 $1,166.5 $761.4 
Enterprise-Wide Information

Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements.

 As of or for the Years Ended December 31,
 202020192018
(in millions)
Net Sales by Geographic Area   
United States$2,516.8 $2,532.7 $2,055.3 
Europe973.6 941.2 885.1 
Japan460.1 444.7 396.8 
Rest of World435.8 429.4 385.6 
$4,386.3 $4,348.0 $3,722.8 
Net Sales by Major Product Area  
Transcatheter Aortic Valve Replacement$2,857.3 $2,737.9 $2,283.8 
Transcatheter Mitral and Tricuspid Therapies41.8 28.2 2.9 
Surgical Structural Heart761.8 841.7 761.6 
Critical Care725.4 740.2 674.5 
$4,386.3 $4,348.0 $3,722.8 
Long-lived Tangible Assets by Geographic Area   
United States$1,084.3 $849.1 $642.1 
Europe192.7 101.5 36.6 
Japan20.4 21.7 6.7 
Rest of World311.0 269.4 214.4 
$1,608.4 $1,241.7 $899.8